Developer docs
API playgroundTry for free, no card

Search company profiles

Autobio Diagnostics

Full company profile

uuid003778s

Namestring
Autobio Diagnostics
Legal namestring
郑州安图生物工程股份有限公司 (Zhengzhou Autobio Bioengineering Co., Ltd.)
Websiteurl
autobio.com.cn
Company typeenum
Public
Founded yearint
1998
Descriptiontext

Autobio Diagnostics (郑州安图生物工程股份有限公司, ticker: 603658) is a publicly listed Chinese in vitro diagnostics (IVD) company headquartered in Zhengzhou, Henan Province, founded in 1998 and listed on the Shanghai Stock Exchange Main Board in September 2016 — the first IVD R&D and manufacturing enterprise to list on the SSE Main Board. The company designs, manufactures, and sells diagnostic instruments, reagents, and integrated laboratory automation systems spanning immunoassay (magnetic particle chemiluminescence), microbiology (mass spectrometry, identification, susceptibility), biochemistry, molecular diagnostics (PCR), coagulation, and next-generation sequencing. It also offers custom laboratory solutions including intelligent laboratory construction, lean management consulting (AutoLean), and quality control software.

The technology stack is anchored by a proprietary magnetic particle chemiluminescence platform with 225+ detection items and a localized microbial mass spectrometry database covering 5,000+ species, supplemented by purpose-built analyzers such as the AutoLumo A9000 (up to 3,200 tests/hour), AutoChem B2000 (2,000 tests/hour), Autof T series mass spectrometers, AutoMolec 3000 PCR systems, and the Autolas X-1 automated assembly line. R&D strength is unusually high for the industry: 2,000+ R&D personnel (30% of total workforce), 18.16% R&D-to-revenue ratio, 6 R&D centers across China and North America, 1,040+ product registration certificates, 2,000+ patents, and 368 EU CE certifications for immunodiagnostic products.

Autobio's revenue model is a B2B enterprise razor/blade model: hardware (analyzers, assembly lines) is sold or placed with hospitals and clinical laboratories, while recurring consumables (reagents, test kits) generate the ongoing revenue stream, supplemented by laboratory services and international distribution. The company sells directly to medical laboratories, hospitals, and clinical testing centers across all 30 Chinese provincial administrative regions and through distribution networks in 110+ countries, with wholly-owned subsidiaries in Indonesia and a reference laboratory in Hungary as of 2026. FY2025 revenue was 4.226 billion CNY with net profit of 1.068 billion CNY (~25% net margin), placing the company among the top-tier Chinese IVD players by scale.

Short descriptiontext

Autobio Diagnostics is a publicly listed Chinese in vitro diagnostics company that develops, manufactures, and sells immunoassay, microbiology, biochemistry, molecular, coagulation, and sequencing instruments, reagents, and automated laboratory systems to hospital laboratories and clinical testing centers across China and 110+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersZhengzhou, China
HQ citystring
Zhengzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices9 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in-vitro diagnostics, diagnostic reagents, immunoassay analyzers, laboratory automation, microbiology testing
Industry3 codes
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
  • Laboratory Analytical Instruments3826
Product category
In-Vitro Diagnostics (IVD)
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1IVD Reagent Sales
TypeHardware Sales
Description

Sale of in vitro diagnostic reagents covering immunodiagnostics, microbiology, biochemistry, molecular diagnostics, and coagulation testing. Products include 1040+ product registrations (as of 2025), including 515 immunodiagnostic registration certificates and 201 biochemical product registrations.

autobio.com.cn
2Diagnostic Instrument Sales
TypeHardware Sales
Description

Manufacturing and sale of automated diagnostic instruments including chemiluminescence analyzers, biochemical analyzers, mass spectrometry systems, molecular diagnostic systems, coagulation analyzers, and automated laboratory assembly lines.

autobio.com.cn
3Laboratory Solutions and Services
TypeProfessional Services
Description

Complete laboratory solutions including intelligent medical laboratory construction, AutoLean lean management consulting services, laboratory quality control services, and laboratory building services.

autobio.com.cn
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 12 records shown
1AutoLumo
Description

Fully automated chemiluminescence immunoassay analyzer series

autobio.com.cn
+11 more records
Core offering1 text field

Autobio Diagnostics develops, manufactures, and sells in-vitro diagnostic (IVD) products including clinical chemistry reagents, immunoassay reagents, microbiology reagents, automated diagnostic analyzers, and laboratory automation systems. The portfolio is targeted at hospital laboratories, independent clinical labs, and other healthcare providers performing routine and specialty diagnostic testing. Its reagent menu spans immunoassay, microbiology, and clinical chemistry applications, complemented by proprietary instruments and total laboratory automation (TLA) platforms that integrate analyzers, reagents, and middleware into unified workflows.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 8000 tests/hour biochemical detection speed with Autolas X-1 Series
+4 more records
Product overview1 text field

安图生物是一家专注于体外诊断试剂和仪器的研发、制造、整合及服务的公司,产品涵盖免疫、微生物、生化、分子、凝血等检测领域,并延伸至测序、质谱、精准检测和智慧化医学实验室等领域。主要产品包括:流水线产品系列(Autolas B-1 Star、Autolas X-1、Autolas A-1、Autolas B-1系列),免疫产品系列(AutoLumo A9000、A6000、A2000 Plus、A1800、S900、AutoFlex 300),生化产品系列(AutoChem B2000、AutoChem B800、TBA-FX8、TBA-2000FR、TBA-120FR),微生物产品系列(Autof T系列质谱、AutoStreak S1800、BC120 Plus、BC120、AutoMic-i600、AutowoMO W500、GLP-F300),分子产品系列(AutoMolec 3000、AutoMolec 1600),凝血产品系列(AutoCimo C6000、Ci-330、Ci-310、Ci-120x),精准检测产品系列(Sikun系列基因测序仪、AISPre 3200、Automs TQ6000、Auto Master、AutoNaseq系列纳米孔测序仪),以及POCT产品系列(呼吸道抗原检测试剂盒等)。公司还提供AutoLean®精益管理解决方案、医学实验室智能化解决方案、实验室质量控制服务等配套服务,为医学实验室提供全面的产品解决方案和整体服务。

Product and service6 records
1Immunoassay diagnostic reagents
CategoryDiagnostic reagents
Description

Clinical immunoassay reagent kits (chemiluminescence and related immunoassay formats) used on Autobio automated immunoassay analyzers to detect and quantify analytes for clinical diagnostics. Targeted at hospital laboratories, independent clinical labs, and other healthcare providers performing routine and specialty immunoassay testing.

2Microbiology diagnostic reagents
CategoryDiagnostic reagents
Description

Reagents and consumables for microbial culture, identification, and antimicrobial susceptibility testing used with Autobio microbiology instruments in clinical microbiology laboratories. Targeted at hospital microbiology labs and reference laboratories performing infectious disease diagnostics.

3Clinical chemistry reagents
CategoryDiagnostic reagents
Description

Reagent kits for clinical chemistry analytes (e.g., liver, renal, lipid, electrolyte, and other routine chemistry panels) run on Autobio clinical chemistry analyzers. Targeted at hospital and clinical laboratories performing high-volume routine chemistry testing.

4Automated immunoassay analyzers
CategoryDiagnostic instruments
Description

Automated chemiluminescence immunoassay analyzer instruments that run Autobio immunoassay reagent kits for clinical diagnostics. Sold to hospital laboratories, independent clinical laboratories, and other healthcare providers; instrument placement drives recurring reagent consumption.

5Microbiology identification and susceptibility analyzers
CategoryDiagnostic instruments
Description

Automated instruments for microbial identification and antimicrobial susceptibility testing used with Autobio microbiology reagents in clinical microbiology laboratories. Targeted at hospital and reference microbiology laboratories.

6Total Laboratory Automation (TLA) systems
CategoryLaboratory automation systems
Description

Integrated laboratory automation track systems that connect pre-analytical, analytical (analyzers), and post-analytical stages into a unified workflow, paired with middleware for laboratory information management. Sold to hospital and reference laboratories seeking consolidated, high-throughput testing operations.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1迈克赛德 (Maccure)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Strategic cooperation in urine analysis field achieving technology, product and market synergies. Expands Autobio's diagnostic offerings in the urinalysis segment.

autobio.com.cn
Strategic tierLegacyTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Acquired in 2003 to establish automated microbiology plate production line and enter reagent scale production stage.

3希肯医疗 (Xikan Medical)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Strategic cooperation in coagulation testing field. Autobio entered the coagulation detection market through this partnership, combining Xikan Medical's expertise with Autobio's comprehensive IVD portfolio.

autobio.com.cn
4佳能 (Canon)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2017-01-01
Description

Strategic integration to obtain Canon biochemical analyzer China distribution rights, expanding Autobio's biochemical product portfolio and market reach.

autobio.com.cn
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Acquisition to build biochemical product line. Established Autobio's presence in biochemical reagent market through strategic consolidation.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Shenzhen Mindray Bio-Medical Electronics
TypeDirect peer
Description

China's largest medical-device/IVD conglomerate with overlapping chemiluminescence, biochemistry, hematology and lab-automation lines; competes head-to-head with Autobio across most PRC hospital tenders.

TypeDirect peer
Description

Global microbiology and immunoassay leader; directly comparable to Autobio's MALDI-TOF Autof T and VITEK-style antimicrobial-susceptibility analyzers in the microbiology segment.

TypeRegional player
Description

China's largest independent clinical reference laboratory network; complement to, and partial competitor with, Autobio's Hungarian reference lab and regional lab-center strategy.

TypeBroad incumbent
Description

Global IVD market leader across immunoassay, biochemistry, molecular and tissue diagnostics; sets the upper-bound performance and pricing benchmark Autobio's chemiluminescence competes against.

TypeBroad incumbent
Description

Broad IVD and lab-automation incumbent (Atellica, ADVIA Centaur); competes in Chinese mid-to-large hospital accounts and in lab-automation-line deals where Autobio's Autolas series is positioned.

TypeDirect peer
Description

Domestic IVD peer with overlapping clinical chemistry, immunoassay and rapid-test product lines; recently partnered with Autobio in urinalysis, indicative of directly competitive Chinese IVD market overlap.

7Shenzhen New Industries Biomedical Engineering (Snibe)
TypeDirect peer
Description

China's leading chemiluminescence immunoassay specialist; competes directly with Autobio's AutoLumo platform in immunoassay menu and installed-base share.

TypeEmerging player
Description

Chinese autoimmune and specialty-immunoassay developer; competes with Autobio's autoimmune antibody detection product series launched in 2024.

9Abbott Diagnostics
TypeBroad incumbent
Description

Global IVD incumbent with strong chemiluminescence and rapid-test portfolios; competes with Autobio in Chinese VBP contexts and in CE-marked international markets.

TypeDirect peer
Description

MALDI-TOF mass spectrometry incumbent (Biotyper) for clinical microbiology identification; directly comparable to Autobio's Autof T series targeting the same clinical MALDI workflow.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability11 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment4 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Autobio Diagnostics

In-Vitro Diagnostics (IVD)autobio.com.cn

Autobio Diagnostics is a publicly listed Chinese in vitro diagnostics company that develops, manufactures, and sells immunoassay, microbiology, biochemistry, molecular, coagulation, and sequencing instruments, reagents, and automated laboratory systems to hospital laboratories and clinical testing centers across China and 110+ countries.

What Autobio Diagnostics does

Autobio Diagnostics (郑州安图生物工程股份有限公司, ticker: 603658) is a publicly listed Chinese in vitro diagnostics (IVD) company headquartered in Zhengzhou, Henan Province, founded in 1998 and listed on the Shanghai Stock Exchange Main Board in September 2016 — the first IVD R&D and manufacturing enterprise to list on the SSE Main Board. The company designs, manufactures, and sells diagnostic instruments, reagents, and integrated laboratory automation systems spanning immunoassay (magnetic particle chemiluminescence), microbiology (mass spectrometry, identification, susceptibility), biochemistry, molecular diagnostics (PCR), coagulation, and next-generation sequencing. It also offers custom laboratory solutions including intelligent laboratory construction, lean management consulting (AutoLean), and quality control software.

The technology stack is anchored by a proprietary magnetic particle chemiluminescence platform with 225+ detection items and a localized microbial mass spectrometry database covering 5,000+ species, supplemented by purpose-built analyzers such as the AutoLumo A9000 (up to 3,200 tests/hour), AutoChem B2000 (2,000 tests/hour), Autof T series mass spectrometers, AutoMolec 3000 PCR systems, and the Autolas X-1 automated assembly line. R&D strength is unusually high for the industry: 2,000+ R&D personnel (30% of total workforce), 18.16% R&D-to-revenue ratio, 6 R&D centers across China and North America, 1,040+ product registration certificates, 2,000+ patents, and 368 EU CE certifications for immunodiagnostic products.

Autobio's revenue model is a B2B enterprise razor/blade model: hardware (analyzers, assembly lines) is sold or placed with hospitals and clinical laboratories, while recurring consumables (reagents, test kits) generate the ongoing revenue stream, supplemented by laboratory services and international distribution. The company sells directly to medical laboratories, hospitals, and clinical testing centers across all 30 Chinese provincial administrative regions and through distribution networks in 110+ countries, with wholly-owned subsidiaries in Indonesia and a reference laboratory in Hungary as of 2026. FY2025 revenue was 4.226 billion CNY with net profit of 1.068 billion CNY (~25% net margin), placing the company among the top-tier Chinese IVD players by scale.

Autobio Diagnostics firmographics

Firmographics
Name
Autobio Diagnostics
Legal name
郑州安图生物工程股份有限公司 (Zhengzhou Autobio Bioengineering Co., Ltd.)
Website
https://autobio.com.cn
Company type
Public
Founded year
1998
Operating status
Operating
Headcount range
101–250 employees
Short description
Autobio Diagnostics is a publicly listed Chinese in vitro diagnostics company that develops, manufactures, and sells immunoassay, microbiology, biochemistry, molecular, coagulation, and sequencing instruments, reagents, and automated laboratory systems to hospital laboratories and clinical testing centers across China and 110+ countries.
Ownership category
akta.pro rank

Where Autobio Diagnostics is headquartered

Location

Headquarters

HQ city
Zhengzhou
HQ country
China
HQ region
Asia

Offices9 records

Markets served

Autobio Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

  1. IVD Reagent Sales: Sale of in vitro diagnostic reagents covering immunodiagnostics, microbiology, biochemistry, molecular diagnostics, and coagulation testing. Products include 1040+ product registrations (as of 2025), including 515 immunodiagnostic registration certificates and 201 biochemical product registrations.
  2. Diagnostic Instrument Sales: Manufacturing and sale of automated diagnostic instruments including chemiluminescence analyzers, biochemical analyzers, mass spectrometry systems, molecular diagnostic systems, coagulation analyzers, and automated laboratory assembly lines.
  3. Laboratory Solutions and Services: Complete laboratory solutions including intelligent medical laboratory construction, AutoLean lean management consulting services, laboratory quality control services, and laboratory building services.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Autobio Diagnostics product offering

Product offering

Core offering

Autobio Diagnostics develops, manufactures, and sells in-vitro diagnostic (IVD) products including clinical chemistry reagents, immunoassay reagents, microbiology reagents, automated diagnostic analyzers, and laboratory automation systems. The portfolio is targeted at hospital laboratories, independent clinical labs, and other healthcare providers performing routine and specialty diagnostic testing. Its reagent menu spans immunoassay, microbiology, and clinical chemistry applications, complemented by proprietary instruments and total laboratory automation (TLA) platforms that integrate analyzers, reagents, and middleware into unified workflows.

Product overview

安图生物是一家专注于体外诊断试剂和仪器的研发、制造、整合及服务的公司,产品涵盖免疫、微生物、生化、分子、凝血等检测领域,并延伸至测序、质谱、精准检测和智慧化医学实验室等领域。主要产品包括:流水线产品系列(Autolas B-1 Star、Autolas X-1、Autolas A-1、Autolas B-1系列),免疫产品系列(AutoLumo A9000、A6000、A2000 Plus、A1800、S900、AutoFlex 300),生化产品系列(AutoChem B2000、AutoChem B800、TBA-FX8、TBA-2000FR、TBA-120FR),微生物产品系列(Autof T系列质谱、AutoStreak S1800、BC120 Plus、BC120、AutoMic-i600、AutowoMO W500、GLP-F300),分子产品系列(AutoMolec 3000、AutoMolec 1600),凝血产品系列(AutoCimo C6000、Ci-330、Ci-310、Ci-120x),精准检测产品系列(Sikun系列基因测序仪、AISPre 3200、Automs TQ6000、Auto Master、AutoNaseq系列纳米孔测序仪),以及POCT产品系列(呼吸道抗原检测试剂盒等)。公司还提供AutoLean®精益管理解决方案、医学实验室智能化解决方案、实验室质量控制服务等配套服务,为医学实验室提供全面的产品解决方案和整体服务。

Differentiator

Problem solved

Functional benefit

Brands

  • AutoLumo: Fully automated chemiluminescence immunoassay analyzer series
  • AutoChem
  • Autolas
  • Autof
  • AutoMolec
  • AutoMic-i600
  • AutoCimo
  • AutoLean
  • BiQAS
  • Sikun
  • AutoNaseq
  • Automs TQ6000

Products and services

  • Immunoassay diagnostic reagents Clinical immunoassay reagent kits (chemiluminescence and related immunoassay formats) used on Autobio automated immunoassay analyzers to detect and quantify analytes for clinical diagnostics. Targeted at hospital laboratories, independent clinical labs, and other healthcare providers performing routine and specialty immunoassay testing.
  • Microbiology diagnostic reagents Reagents and consumables for microbial culture, identification, and antimicrobial susceptibility testing used with Autobio microbiology instruments in clinical microbiology laboratories. Targeted at hospital microbiology labs and reference laboratories performing infectious disease diagnostics.
  • Clinical chemistry reagents Reagent kits for clinical chemistry analytes (e.g., liver, renal, lipid, electrolyte, and other routine chemistry panels) run on Autobio clinical chemistry analyzers. Targeted at hospital and clinical laboratories performing high-volume routine chemistry testing.
  • Automated immunoassay analyzers Automated chemiluminescence immunoassay analyzer instruments that run Autobio immunoassay reagent kits for clinical diagnostics. Sold to hospital laboratories, independent clinical laboratories, and other healthcare providers; instrument placement drives recurring reagent consumption.
  • Microbiology identification and susceptibility analyzers Automated instruments for microbial identification and antimicrobial susceptibility testing used with Autobio microbiology reagents in clinical microbiology laboratories. Targeted at hospital and reference microbiology laboratories.
  • Total Laboratory Automation (TLA) systems Integrated laboratory automation track systems that connect pre-analytical, analytical (analyzers), and post-analytical stages into a unified workflow, paired with middleware for laboratory information management. Sold to hospital and reference laboratories seeking consolidated, high-throughput testing operations.

Quantifiable outcome

  • 8000 tests/hour biochemical detection speed with Autolas X-1 Series
  • +4 more outcomes

Companies that use Autobio Diagnostics

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles1 record

Autobio Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability11 records

Feature5 records

Autobio Diagnostics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and legacy.

  • 迈克赛德 (Maccure)coreStrategic or Co-development Partner · 1 January 2025Strategic cooperation in urine analysis field achieving technology, product and market synergies. Expands Autobio's diagnostic offerings in the urinalysis segment.
  • 郑州绿科生物工程有限公司 (Zhengzhou Lvke Bio-Engineering)legacyStrategic or Co-development Partner · 1 January 2024Acquired in 2003 to establish automated microbiology plate production line and enter reagent scale production stage.
  • 希肯医疗 (Xikan Medical)coreStrategic or Co-development Partner · 1 January 2021Strategic cooperation in coagulation testing field. Autobio entered the coagulation detection market through this partnership, combining Xikan Medical's expertise with Autobio's comprehensive IVD portfolio.
  • 佳能 (Canon)coreChannel Partner/ Reseller/ Distributor · 1 January 2017Strategic integration to obtain Canon biochemical analyzer China distribution rights, expanding Autobio's biochemical product portfolio and market reach.
  • 北京百奥泰康生物技术有限公司 (Beijing BioBAY Bio-Tech)coreStrategic or Co-development Partner · 1 January 2017Acquisition to build biochemical product line. Established Autobio's presence in biochemical reagent market through strategic consolidation.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Autobio Diagnostics competitors and assessment

Company assessment

Direct peers

  • Shenzhen Mindray Bio-Medical Electronics: China's largest medical-device/IVD conglomerate with overlapping chemiluminescence, biochemistry, hematology and lab-automation lines; competes head-to-head with Autobio across most PRC hospital tenders.
  • bioMérieux: Global microbiology and immunoassay leader; directly comparable to Autobio's MALDI-TOF Autof T and VITEK-style antimicrobial-susceptibility analyzers in the microbiology segment.
  • Maccura Biotechnology: Domestic IVD peer with overlapping clinical chemistry, immunoassay and rapid-test product lines; recently partnered with Autobio in urinalysis, indicative of directly competitive Chinese IVD market overlap.
  • Shenzhen New Industries Biomedical Engineering (Snibe): China's leading chemiluminescence immunoassay specialist; competes directly with Autobio's AutoLumo platform in immunoassay menu and installed-base share.
  • Bruker: MALDI-TOF mass spectrometry incumbent (Biotyper) for clinical microbiology identification; directly comparable to Autobio's Autof T series targeting the same clinical MALDI workflow.

Regional players

  • KingMed Diagnostics: China's largest independent clinical reference laboratory network; complement to, and partial competitor with, Autobio's Hungarian reference lab and regional lab-center strategy.

Broad incumbents

  • Roche Diagnostics: Global IVD market leader across immunoassay, biochemistry, molecular and tissue diagnostics; sets the upper-bound performance and pricing benchmark Autobio's chemiluminescence competes against.
  • Siemens Healthineers: Broad IVD and lab-automation incumbent (Atellica, ADVIA Centaur); competes in Chinese mid-to-large hospital accounts and in lab-automation-line deals where Autobio's Autolas series is positioned.
  • Abbott Diagnostics: Global IVD incumbent with strong chemiluminescence and rapid-test portfolios; competes with Autobio in Chinese VBP contexts and in CE-marked international markets.

Emerging players

  • Yhlo (Shenzhen Yhlo Biotech): Chinese autoimmune and specialty-immunoassay developer; competes with Autobio's autoimmune antibody detection product series launched in 2024.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Autobio Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Autobio Diagnostics leadership team

Management profile

Number of profiles

Autobio Diagnostics subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Autobio Diagnostics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Autobio Diagnostics M&A and investment

M&A and investment

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Autobio Diagnostics

What does Autobio Diagnostics do?

Autobio Diagnostics develops, manufactures, and sells in-vitro diagnostic (IVD) products including clinical chemistry reagents, immunoassay reagents, microbiology reagents, automated diagnostic analyzers, and laboratory automation systems. The portfolio is targeted at hospital laboratories, independent clinical labs, and other healthcare providers performing routine and specialty diagnostic testing. Its reagent menu spans immunoassay, microbiology, and clinical chemistry applications, complemented by proprietary instruments and total laboratory automation (TLA) platforms that integrate analyzers, reagents, and middleware into unified workflows.

Is Autobio Diagnostics a public or private company?

Autobio Diagnostics is a public company. It is classified as public and is currently operating.

When was Autobio Diagnostics founded?

Autobio Diagnostics was founded in 1998. It employs 101 to 250 people.

Where is Autobio Diagnostics based?

Autobio Diagnostics is headquartered in Zhengzhou, China, in the Asia region.

How does Autobio Diagnostics make money?

Three revenue lines are on record. IVD Reagent Sales are the primary driver. The others are diagnostic Instrument Sales and laboratory Solutions and Services.

Who are Autobio Diagnostics's main competitors?

Direct peers on record are Shenzhen Mindray Bio-Medical Electronics, bioMérieux, Maccura Biotechnology, Shenzhen New Industries Biomedical Engineering (Snibe) and Bruker. KingMed Diagnostics is listed as a regional player. Broad incumbents are Roche Diagnostics, Siemens Healthineers and Abbott Diagnostics. Yhlo (Shenzhen Yhlo Biotech) is listed as an emerging player.

Does Autobio Diagnostics have an API?

No public API is recorded for Autobio Diagnostics.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
36krTop 5 Most Profitable Listed Medical Device Enterprises: One Profits From Investments, Another Earns By Selling GlovesIn H1 2026, 175 A+H listed medical device companies reported results, with 140 A-share firms generating 1.31411 trillion yuan in revenue. Mindray led net profit at 5.047 billion yuan, while Intco Medical ranked fourth with 904 million yuan, and six of the top 10 saw declining profits.PR NewswireCoronavirus (COVID-19) Update: Daily RoundupThe U.S. Food and Drug Administration revoked the emergency use authorization for Autobio Diagnostics Co., Ltd.'s Anti-SARS-CoV-2 Rapid Test due to accuracy concerns. The FDA also issued a joint warning letter with the Federal Trade Commission to Canadian Chaga for selling fraudulent products claiming to treat or prevent COVID-19.FinSMEsMobidiag Receives €10M Equity InvestmentMobidiag, a Finnish molecular diagnostics company, completed a €10M equity investment from Autobio Diagnostics. The funds will support product portfolio growth, assay development for its Novodiag system, and manufacturing and commercial expansion. The company's platform detects infectious diseases and antibiotic resistance in about an hour.Business Wire BlogMobidiag Announces Joint Venture with Autobio Diagnostics and €10m Equity InvestmentMobidiag announced a joint venture with Autobio Diagnostics to commercialize its Novodiag platform in China, with Autobio investing €8m for a 65% stake. Mobidiag received a separate €10m equity investment to fund product expansion and development.